Harm Reduction · Clinical Depth

AAS Personalisation
Bloodwork & Genetics Guide

A comprehensive pharmacogenomics-informed framework for understanding anabolic-androgenic steroids — compound profiles, biomarker monitoring, CYP enzyme phenotyping, and individualised cycle decision logic.

!
Harm Reduction Notice This guide is provided strictly for educational and harm reduction purposes. Anabolic-androgenic steroids are controlled substances in many jurisdictions. Use without medical supervision carries significant health risks including cardiovascular, hepatic, endocrine, and psychiatric effects. All information here is intended to reduce harm for those who have made an informed decision to use — not to encourage use. Regular medical monitoring, honest disclosure to healthcare providers, and conservative dosing are strongly advised. This document does not constitute medical advice.

Compound Library

Click any compound to expand full profile. Anabolic:Androgenic ratios are relative to testosterone (100:100). Bar values are normalised for visual comparison only.

Baseline Blood Panel

Every panel below should be established before initiating any cycle. Red flags (absolute contraindications) are noted per marker. Click to expand optimal pre-cycle ranges and what each marker predicts about individual response.

Pharmacogenomics & Genetic Markers

Genetic variants dramatically alter how compounds are metabolised, how strongly androgen receptors respond, and how much cardiovascular and hepatic risk is conferred. Sources: 23andMe raw data, AncestryDNA, or clinical pharmacogenomic panels (GeneSight, Genomind, Mayo GEP).

On-Cycle Monitoring Protocol

Frequency recommendations assume a standard 12–16 week cycle. Adjust for compound hepatotoxicity, cardiovascular risk profile, and individual genetics.

Monitoring schedule by marker category

Key on-cycle correlations

Ancillaries & Support Compounds

Ancillary selection should be driven by bloodwork and genetics — not prophylactically applied to every cycle. Over-use of AIs, for example, crushes estrogen and worsens lipids, joints, libido, and neurological function.

Cycle Builder Decision Logic

Pattern-matching logic: given your bloodwork results and genetic phenotype, here is what the data points toward. These are decision inputs, not prescriptions.

Biomarker + genetic pattern → cycle implication

PCT & Recovery Logic

Post-cycle pattern → recovery protocol
AAS Personalisation Guide · Harm Reduction · Educational Use Only Always interpret with a qualified physician